Lotronex - Another Pharmaceutical Backfire - Page 2© Adelle Vancil Tilton
Page 2
Aug 25, 2000
Wouldn't it make more sense to reverse this procedure and use the life saving potential of a new drug to quickly attempt treatment on a terminal patient and allow the person with a lesser illness to use traditional treatments until a new drug can be thoroughly tested and evaluated? Perhaps this is a proposal that should receive a close look by the administrators at the Food and Drug Administration. Recently, it seems to me, as well as others, that too many drugs are slipping through, only to be recalled after distribution. More caution would help to prevent events like the scenario above, and ensure that patients really do receive the best treatment possible and physicians receive the best recommendations for treatment options by the pharmaceutical companies.
Go To Page:
1
2
The copyright of the article Lotronex - Another Pharmaceutical Backfire - Page 2 in Public Health Issues is owned by . Permission to republish Lotronex - Another Pharmaceutical Backfire - Page 2 in print or online must be granted by the author in writing.
Well, I am glad you stumbled in too. I hope you come back. Yup, the Pyr is now almost a year and is over 120 lbs. I just wish he didn't think he was still a puppy!
...
-- posted by EspressoMoment
|
what a great, informative article. Unfortunately, the scenario you describe happens all too often. Thank you for informing us. I'm so glad I stumbled upon your topic!Renie PS. A Great Pyrene
...
-- posted by Renie_Burghardt
|
I agree with your comments. I think that the FDA has the cart before the horse. But again, doesn't it always come back to money. A non-terminal patient has a lot more money over a period of time to
...
-- posted by EspressoMoment
|
This is an excellent article. I have wondered the same thing. I thing a lot of people have. Why do they deny terminal patients a chance and play roulet with everyone else. As you said, it makes no sen
...
|
For a complete listing of article comments, questions, and other discussions related to
Adelle Vancil Tilton's
Public Health Issues topic, please visit the Discussions page.
|
